ONL Therapeutics Inc., an Ann Arbor-based spinoff from theUniversity of Michigan, has received a crucial orphan-drug designation from theU.S. Food and Drug Administrationfor its lead compound, which has the working name of ONL1204.

The drug, expected to go into human trials this year, is used to limit the damage caused to patients who suffer retinal detachments.